Paul Tudor Jones’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Paul Tudor Jones’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,760	Closed	-$1.98M	–	3058
2023 Q1	$1.98M	Buy	+21,760	New	+$1.28M	0.03%	791
2022 Q4	–	Sell	-11,833	Closed	-$297K	–	2970
2022 Q3	$297K	Buy	11,833 +302	+3%	+$8.37K	0.01%	1801
2022 Q2	$350K	Sell	11,531 -1,644	-12%	-$49K	0.01%	1478
2022 Q1	$432K	Buy	13,175 +4,293	+48%	+$127K	0.01%	1357
2021 Q4	$234K	Sell	8,882 -11,102	-56%	-$859K	﹤0.01%	2045
2021 Q3	$2.01M	Buy	19,984 +4,360	+28%	+$511K	0.03%	697
2021 Q2	$2.21M	Sell	15,624 -6,461	-29%	-$730K	0.04%	518
2021 Q1	$2.2M	Buy	22,085 +8,859	+67%	+$1.03M	0.04%	482
2020 Q4	$1.64M	Buy	+13,226	New	+$1.74M	0.05%	497
2020 Q3	–	Sell	-7,666	Closed	-$1.2M	–	1602
2020 Q2	$1.2M	Buy	7,666 +1,740	+29%	+$265K	0.06%	421
2020 Q1	$855K	Sell	5,926 -2,340	-28%	-$452K	0.08%	296
2019 Q4	$1.69M	Buy	+8,266	New	+$1.51M	0.08%	342

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Paul Tudor Jones's RETA Position: Q2 2023 in Review

Paul Tudor Jones sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 21,760 shares — an estimated $1.98M sold.

Paul Tudor Jones first reported a position in RETA in Q4 2019 and held it in 12 quarters. The position peaked at $2.21M in Q2 2021. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Paul Tudor Jones reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Paul Tudor Jones sold 21,760 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $1.98M.
Paul Tudor Jones first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 12 quarters.
Paul Tudor Jones's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.21M in Q2 2021.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.